Antiviral Drugs - Israel | Statista Market Forecast

The projected revenue for the Antiviral Drugs market in Israel is expected to reach US$123.30m in 2024.
Looking ahead, the market is anticipated to grow at an annual growth rate of 1.76% between 2024 and 2029, resulting in a market volume of US$134.50m by 2029.
It is worth noting that, in global comparison, United States is expected to generate the highest revenue in this market, with an estimated amount of US$30.64bn in 2024.
Israel is at the forefront of developing innovative antiviral drugs, leveraging its strong pharmaceutical research and development capabilities.

Definition:
The Antiviral Drugs market includes treatments against viruses and virus-induced conditions, such as human immunodeficiency viruses (HIV), hepatitis B and C viruses (HBV and HCV), and Ebola. Therapies for the coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), are also included. HIV therapies also encompass highly active antiretroviral therapies (HAART) and post-exposure prophylaxis. In contrast to antibiotics, antivirals do not destroy the virus but rather inhibit its development.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, AbbVie, Merck

HIV
Hepatitis B and hepatitis C
Ebola
COVID-19

Vaccines
Antibiotics
Immunosuppressants
In vitro diagnostics and rapid tests

The demand for antiviral drugs in Israel has been on the rise in recent years, driven by various factors that are unique to the country.

Customer preferences: Israeli consumers are increasingly demanding antiviral drugs as they become more aware of the benefits of these drugs in treating viral infections. This trend is particularly evident among the elderly population, who are more vulnerable to viral infections and are therefore more likely to seek out antiviral medications.

Trends in the market: One of the key trends in the Israeli antiviral drug market is the growing demand for drugs that can treat viral infections such as hepatitis C and HIV. This trend is being driven by the increasing prevalence of these diseases in the country, as well as the growing awareness of the benefits of early treatment.Another trend that is shaping the Israeli antiviral drug market is the increasing use of combination therapies. Many antiviral drugs are now being used in combination with other drugs to increase their effectiveness and reduce the risk of drug resistance.

Local special circumstances: Israel has a unique healthcare system that is characterized by a high level of government involvement. This has led to the development of a strong pharmaceutical industry in the country, with many local companies specializing in the production of antiviral drugs.In addition, Israel is home to a large number of research institutions and universities that are focused on developing new antiviral drugs. This has helped to drive innovation in the industry and has led to the development of many new drugs that are now available on the market.

Underlying macroeconomic factors: The Israeli economy has been growing steadily in recent years, with a focus on high-tech industries and innovation. This has helped to create a favorable environment for the pharmaceutical industry, which has been able to attract investment and develop new drugs.In addition, the Israeli government has been supportive of the pharmaceutical industry, providing funding for research and development and offering tax incentives to companies that invest in the sector. This has helped to create a stable and supportive environment for the antiviral drug market in Israel.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.